Treatment
Treatment Of Physician's Choice clinical trials
We’re tracking 47 recruiting studies that include Treatment Of Physician's Choice, each written for real people, not researchers, below.
Recruiting studies
- NCT06656624RecruitingPhase 2
Ribociclib plus hormone therapy for advanced breast cancer
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
Nanjing, JiangsuAges 18–99 - NCT07265674RecruitingPhase 3
Study of nanvuranlat for advanced bile duct cancer
This study tests a new drug called nanvuranlat for people with advanced bile duct cancer that has gotten worse after platinum-based chemotherapy. It compares nanvuranlat with the doctor's choice of standard treatments to see which works better.
Duarte, CaliforniaAges 18 years+ - NCT06643585RecruitingPhase 3
Comparing T-DXd to standard therapy for molecular relapse in early breast cancer
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
UlmAges 18–75 - NCT06243393RecruitingPhase 2/Phase 3
Sacituzumab govitecan for advanced colorectal cancer
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06279104Recruiting
Comparing treatments for ovarian clear cell carcinoma
This study compares different ways to treat ovarian clear cell carcinoma, a rare type of ovarian cancer. It is for women whose cancer has come back or not gone away after platinum chemotherapy, or those newly diagnosed.
Wuhan, HubeiAges 18–75 - NCT06080620Recruiting
Choosing the best treatment for locally advanced breast cancer
This study looks at different treatment plans for women with newly diagnosed, locally advanced breast cancer (stage IIIb-IIIc). It aims to find the most effective combination of surgery, chemotherapy, and radiotherapy. If you are a woman aged 18-70 with this diagnosis and your tumor can be surgically removed, this trial may be an option for you.
BeijingAges 18–70 - NCT06264180RecruitingPhase 3
Viral therapy and nivolumab for advanced melanoma
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
Gilbert, ArizonaAges 12 years+ - NCT07652125Recruiting
RGL-270 vaccine plus immunotherapy for advanced lung cancer
This trial tests a new cancer vaccine (RGL-270) combined with immunotherapy drugs for advanced non-small cell lung cancer. The vaccine is designed to train your immune system to recognize and fight your specific cancer.
Guangzhou, Other (Non U.s.)Ages 18 years+ - NCT07606599RecruitingPhase 3
New drug BL-M07D1 for advanced biliary tract cancer
This trial tests a new drug called BL-M07D1 against standard chemotherapy for biliary tract cancer that has spread or is locally advanced and has stopped responding to platinum-based chemotherapy. The trial is looking for patients whose cancer has a specific genetic marker to see if this new treatment works better.
Hefei, AnhuiAges 18–75 - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04510740Recruiting
Liver cancer registry study to improve future care
This study records information about people with liver cancer (hepatocellular or bile duct cancer) to help improve how care is planned and delivered. You may join a patient-experience part before or soon after starting your first main treatment.
Multiple SitesAges 18 years+ - NCT05129969Recruiting
Registry for advanced ovarian or endometrial cancer patients
This registry collects information from people with advanced ovarian or endometrial cancer to better understand care and outcomes. It may help researchers and doctors learn which treatments work best for different patients.
Multiple LocationsAges 18 years+ - NCT06138990RecruitingPhase 2
Personalized treatment matching for relapsed or refractory AML
This trial uses a special lab test (pharmacoscopy) to help your doctor choose the best standard chemotherapy for your AML. It is for people whose leukemia has returned or not responded to treatment, and who are strong enough for intensive chemotherapy.
Bern, Canton of BernAges 18–70 - NCT06743126RecruitingPhase 3
IMA203 vs standard treatment for advanced skin cancer
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Phoenix, ArizonaAges 18 years+ - NCT06857175RecruitingPhase 3
Comparing a new drug to standard chemo for advanced bladder cancer
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06942442RecruitingPhase 2
Tebentafusp for advanced clear cell sarcoma
This trial tests if a drug called tebentafusp can help people with advanced clear cell sarcoma that cannot be removed by surgery or has spread. It is for people with a specific immune marker (HLA-A*02:01) whose disease has gotten worse.
Los Angeles, CaliforniaAges 18 years+ - NCT07203729RecruitingPhase 2
Trastuzumab rezetecan for her2-low breast cancer with visceral crisis
This trial tests a new antibody-drug combination called trastuzumab rezetecan (SHR-A1811) in people with a specific type of breast cancer (HER2-low) that has spread and is causing serious organ problems (visceral crisis). The goal is to see if this treatment can help when organs like the liver or lungs are rapidly failing due to the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06861244RecruitingPhase 2
ETMR brain tumor trial for children
This trial is for children with a rare brain tumor (ETMR) who have not had radiation. Depending on how much tumor is left after surgery and if it has spread, the study compares giving radiation early versus high-dose chemotherapy.
Birmingham, AlabamaAges Any age - NCT05761093Recruiting
Share your treatment preferences for metastatic prostate cancer
This study asks people with metastatic prostate cancer and their doctors about what benefits and risks matter most when choosing treatment. Your answers can help improve how treatment options are discussed in Hong Kong.
ShatinAges 18 years+ - NCT07001618RecruitingPhase 2
Fecal transplant with immunotherapy for advanced lung cancer
This trial tests whether taking an oral fecal transplant (MaaT033) along with the immunotherapy drug cemiplimab can help people whose lung cancer stopped responding after antibiotics. It's for people with advanced non-small cell lung cancer whose cancer got worse after standard immunotherapy.
DijonAges 18 years+ - NCT07542769Recruiting
Mindfulness Training Choice for Pediatric Residents
This study helps pediatric doctors-in-training learn mindfulness (a stress-relief technique) while letting them choose how they learn it. Researchers want to see if giving residents control over their learning makes mindfulness more helpful for managing work stress.
Chicago, IllinoisAges Any age - NCT07603856RecruitingPhase 2
Combining Immunotherapy and Radiation for Advanced Lung Cancer
This study tests whether adding focused radiation therapy to immunotherapy can help patients with advanced non-small cell lung cancer whose cancer has progressed despite prior immunotherapy. The goal is to see if this combination works better than immunotherapy alone.
Chicago, IllinoisAges 18 years+ - NCT07236944RecruitingPhase 4
Testing pivmecillinam pills for E. coli kidney infection
This trial tests if a switch to pivmecillinam pills after IV antibiotics works as well as standard oral antibiotics for E. coli febrile urinary tract infections. It aims to simplify treatment for patients who are already stable.
HaukelandAges 18 years+
Common questions
- Are there clinical trials studying Treatment Of Physician's Choice?
- Yes. Clin2 currently lists 47 recruiting studies that include Treatment Of Physician's Choice, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Treatment Of Physician's Choice trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Treatment Of Physician's Choice an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Treatment Of Physician's Choice or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.